Xeris Biopharma Holdings
D

XERS

15.190
USD
2.10
(16.04%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
327,610
الربح لكل سهم
-0
العائد الربحي
-
P/E
-152
حجم السوق
2,769,445,448
أصول ذات صلة

العنوان: Xeris Biopharma Holdings

القطاع: الرعاية الصحية
الصناعة: Drug Manufacturers - Specialty & Generic
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

أسئلة شائعة حول سهم Xeris Biopharma Holdings